Voyager Therapeutics Inc
Research Voyager Therapeutics Inc (VYGR) on Bullrun: market cap USD 216.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVYGR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 216.31M
- Financial periodFY2025
- RevenueUSD 40.37M
- Revenue growth-49.5%
- Net income-USD 119.72M
- Free cash flow-USD 135.06M
Valuation Snapshot
latest market cap is USD 216.31M.
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease;
Frequently asked questions
What is Voyager Therapeutics Inc's market cap?
Voyager Therapeutics Inc's market capitalization is USD 216.31M.
What does Voyager Therapeutics Inc do?
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.